AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort)

Recruitingn/aAges any - anyAllNantes University Hospital
💬

In plain words

What the trial is, and whether it could suit you

Our primary objective with this cohort will be to define the different phenotypes of acute hidrosadenitis, the characterization of which is essential to define suitable therapeutic approaches. Indeed, our recent data allow us to note that there would be different phenotypes of acute hidrosadenitis and therefore different pathologies inducing different follow-ups and care.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patient diagnosed with acute hidrosadenitis by a dermatologist * Patient agreeing to be part of the study Exclusion Criteria: * Major under guardianship * Protected persons
💊

What it tests

  • no interventional study
📍

Where

13 sites
CHU Angers
Angers, France
Chru Brest
Brest, France
CHD Vendée
La Roche-sur-Yon, France
CH La Rochelle
La Rochelle, France
CH
Le Mans, France
CH bretagne sud
Lorient, France
CHU de Nantes - Dermatologie
Nantes, France
Chr D'Orléans
Orléans, France

…and 5 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy